Lilly budgets additional $5.3B for tirzepatide API factory in Indiana

Eli Lil­ly is fur­ther boost­ing man­u­fac­tur­ing in its home state of In­di­ana.

The com­pa­ny said it is al­lo­cat­ing an ad­di­tion­al $5.3 bil­lion in­to its bud­get to build an ac­tive phar­ma­ceu­ti­cal in­gre­di­ent (API) pro­duc­tion fa­cil­i­ty for its block­buster di­a­betes and weight loss drugs.

This new in­vest­ment is more than dou­ble Lil­ly’s ear­li­er $3.7 bil­lion com­mit­ment to the Lebanon, IN, site. With the fund­ing boost, the build will now cost $9 bil­lion and add 200 jobs for en­gi­neers, sci­en­tists, op­er­at­ing and lab­o­ra­to­ry tech­ni­cians, for a new to­tal of 900 em­ploy­ees, ac­cord­ing to a Fri­day re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.